Antibodies used for in situ immunofluorescence
| Antigen . | Monoclonal . | Isotype . | Conjugate . | Concentration for labeling . | Major specificities . | Source . |
|---|---|---|---|---|---|---|
| CD3 | UCHT1 | IgG1 | — | Ascites | T lymphocytes | PB |
| 1/200 | ||||||
| CD11b | OKM1 | IgG2b | — | 1/20 | Monocytes, MΦ, granulocytes | O |
| CD11c | KB90 | IgG1 | — | 1/10 | DCs, monocytes, MΦ, granulocytes | D |
| CD14 | My-4 | IgG2b | — | 25 μg/mL | Monocytes, MΦ | C |
| CD20 | B1 | IgG2a | — | 1/20 | B lymphocytes | C |
| CD83 | HB15a | IgG2b | — | Ascites | DCs, activated B and T lymphocytes | T |
| 1/500 | ||||||
| CD86 | FUN-1 | IgG1 | — | 10 μg/mL | DCs, activated B lymphocytes | P |
| HLA-DR | B8.12.2 | IgG2b | FITC | 1/10 | B lymphocytes, MΦ, DCs | BD |
| Antigen . | Monoclonal . | Isotype . | Conjugate . | Concentration for labeling . | Major specificities . | Source . |
|---|---|---|---|---|---|---|
| CD3 | UCHT1 | IgG1 | — | Ascites | T lymphocytes | PB |
| 1/200 | ||||||
| CD11b | OKM1 | IgG2b | — | 1/20 | Monocytes, MΦ, granulocytes | O |
| CD11c | KB90 | IgG1 | — | 1/10 | DCs, monocytes, MΦ, granulocytes | D |
| CD14 | My-4 | IgG2b | — | 25 μg/mL | Monocytes, MΦ | C |
| CD20 | B1 | IgG2a | — | 1/20 | B lymphocytes | C |
| CD83 | HB15a | IgG2b | — | Ascites | DCs, activated B and T lymphocytes | T |
| 1/500 | ||||||
| CD86 | FUN-1 | IgG1 | — | 10 μg/mL | DCs, activated B lymphocytes | P |
| HLA-DR | B8.12.2 | IgG2b | FITC | 1/10 | B lymphocytes, MΦ, DCs | BD |
LC, Langerhans cells; MΦ, macrophages; NK, natural killer; IgG, immunoglobulin G. Antibodies were obtained from: BD, Becton-Dickinson, Pont-de-Claix, France; C, Coulter, Margency, France; D, Dako, Denmark; P, Pharmingen, San Diego, CA; PB, Dr P. C. Beverley, University College London Medical School, United Kingdom; T, Dr T. F. Tedder, Duke University.